跨子类金属β-乳糖酶抑制剂:从指导设计的结构和催化共同点
Yanhong Zhang1, Zhenyang Liang1, Shuai Wang1
1State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, PR China.
European journal of medicinal chemistry
|March 8, 2025
概括
金属β-乳酸酶 (MβLs) 导致广泛的抗生素耐药性. 本综述探讨了金属β-乳糖酶抑制剂 (MβLIs) 和设计策略,以对抗耐药性病原体.
科学领域:
- 药用化学 医学化学
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
背景情况:
- 金属β-乳酸酶 (MβLs) 是抗生素耐药性的重要原因.
- 它们多样化的抵抗机制构成了全球健康威胁.
- 广谱抑制剂对于对抗MβL介导的耐药性至关重要.
研究的目的:
- 审查具有跨类活性的金属β-乳糖酶抑制剂 (MβLIs).
- 分析当前的MβLI,包括它们的结构,机制和活动.
- 讨论开发新型跨子类MβLIs的实际设计策略.
主要方法:
- 关于金属β-乳糖酶抑制剂及其特性的文献综述.
- 对MβLI开发的四个关键设计策略的分析.
- 详细检查抑制剂的化学结构和机制.
主要成果:
- 鉴定了对各种MβLs表现出跨类活性的MβLIs.
- 详细介绍了当前抑制剂的化学结构,作用机制和跨类活动.
- 总结了设计跨子类MβLIs的四个有效策略.
结论:
- 目前的MβLIs和设计策略为打击抗生素耐药性提供了有希望的途径.
- 讨论的战略为开发下一代MβLIs提供了一个框架.
- 有效的MβLIs对于应对耐药细菌感染日益增长的挑战至关重要.
相关概念视频
Combined Effects of Drugs: Synergism
3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.7K
Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K
Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K


